eis-12656
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 9, 2024 (NCT06525298)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CHD1L inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06525298 | Phase 1/Phase 2 (Phase 2) | Sep 9, 2024 | Eisbach Bio GmbH, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisbach Bio GmbH | For profit | 1 | 1 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1